Tìm theo
Rifampicin
Các tên gọi khác (5 ) :
  • 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin sv
  • RFP
  • Rifampicina
  • Rifampicinum
  • Rifampin
Thuốc trị ký sinh trùng, chống nhiễm khuẩn
Thuốc Gốc
Small Molecule
CAS: 13292-46-1
ATC: J04AB02
ĐG : AAIPharma Inc. , http://www.aaipharma.com
CTHH: C43H58N4O12
PTK: 822.9402
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C43H58N4O12
Phân tử khối
822.9402
Monoisotopic mass
822.40512334
InChI
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
InChI Key
InChIKey=JQXXHWHPUNPDRT-WLSIYKJHSA-N
IUPAC Name
(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-N-(4-methylpiperazin-1-yl)carboximidoyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate
Traditional IUPAC Name
(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-N-(4-methylpiperazin-1-yl)carboximidoyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1,3,5(28),9,19,21,25(29),26-octaen-13-yl acetate
SMILES
CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(O)C(\C=N\N4CCN(C)CC4)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(O)=C2C(O)=C3C
Độ tan chảy
183 °C
Độ hòa tan
1400 mg/L (at 25 °C)
logP
2.7
logS
-4.3
pKa (strongest acidic)
6.9
pKa (Strongest Basic)
7.53
PSA
220.15 Å2
Refractivity
225.58 m3·mol-1
Polarizability
86.46 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
14
H Bond Donor Count
6
Physiological Charge
1
Number of Rings
5
Bioavailability
0
pKa
1.7
Dược Lực Học : Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.
Cơ Chế Tác Dụng : A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death.
Dược Động Học :
▧ Absorption :
Well absorbed from gastrointestinal tract.
▧ Protein binding :
89%
▧ Metabolism :
Primarily hepatic, rapidly deacetylated.
▧ Route of Elimination :
Less than 30% of the dose is excreted in the urine as rifampin or metabolites.
▧ Half Life :
3.35 (+/- 0.66) hours
▧ Clearance :
* 0.19 +/- 0.06 L/hr/kg [300 mg IV] * 0.14 +/- 0.03 L/hr/kg [600 mg IV]
Độc Tính : LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness
Chỉ Định : For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
Tương Tác Thuốc :
  • Abiraterone Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely.
  • Acenocoumarol Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.
  • Acetohexamide Rifampin may decrease the effect of sulfonylurea, acetohexamide.
  • Alfentanil Rifampin reduces levels and efficacy of alfentanil
  • Aminophylline Rifampin decreases the effect of theophylline
  • Amiodarone Rifampin decreases the effect of amiodarone
  • Amitriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed.
  • Amoxapine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed.
  • Amprenavir In presence of rifampin anticipate decrease of amprenavir efficiency
  • Anisindione Rifampin may decrease the anticoagulant effect of anisindione.
  • Aprepitant The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant.
  • Artemether Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. John’s wort is contraindicated with Coartem Tablets.
  • Atazanavir Rifampin reduces levels and efficacy of atazanavir
  • Atorvastatin Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed.
  • Atovaquone Rifampin may decrease the effect of atovaquone.
  • Bedaquiline Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided.
  • Bendamustine CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine.
  • Betamethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone.
  • Bisoprolol Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism.
  • Boceprevir Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Bosutinib Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely.
  • Bromazepam Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed.
  • Bupropion Rifampin reduces bupropion levels
  • Buspirone Rifampin decreases the effect of buspirone
  • Cabazitaxel Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy.
  • Canagliflozin Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily.
  • Caspofungin Decreased levels/effects of caspofungin
  • Celecoxib Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed.
  • Cerivastatin Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed.
  • Chloramphenicol Rifampin decreases the effect of chloramphenicol
  • Chlorpropamide Rifampin may decrease the effect of sulfonylurea, chlorpropamide.
  • Clarithromycin The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin.
  • Clomipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed.
  • Clozapine Rifampin decreases the effect of clozapine
  • Cortisone acetate The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate.
  • Crizotinib Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
  • Crizotinib Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely.
  • Cyclosporine The rifamycin decreases the effect of cyclosporine
  • Dabigatran etexilate P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
  • Dabrafenib Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy.
  • Dapsone Decreased levels of dapsone
  • Dasatinib Rifampin may decrease the serum level and efficacy of dasatinib.
  • Delavirdine Rifampin decreases the effect of delavirdine
  • Desipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed.
  • Dexamethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone.
  • Diazepam Rifampin may decrease the effect of the benzodiazepine, diazepam.
  • Diclofenac Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac.
  • Dicoumarol Rifampin may decrease the anticoagulant effect of dicumarol.
  • Diltiazem Rifampin decreases levels of diltiazem
  • Disopyramide Rifampin decreases the effect of disopyramide
  • Doxepin The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed.
  • Doxycycline The rifamycin decreases the effect of doxycycline
  • Dyphylline Rifampin decreases the effect of theophylline
  • Enalapril Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed.
  • Erlotinib Decreased levels/effect of erlotinib
  • Erythromycin The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin.
  • Ethinyl Estradiol This product may cause a slight decrease of contraceptive effect
  • Ethotoin Rifampin decreases the effect of the hydantoin
  • Etoricoxib Rifampin reduces levels and efficacy of etoricoxib
  • Fentanyl Rifampin may decrease the serum level and therapeutic effect of fentanyl.
  • Fluconazole Rifampin may decrease the effect of fluconazole.
  • Fludrocortisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone.
  • Fluvastatin Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed.
  • Fosamprenavir Rifampin may decrease the effectiveness of fosamprenavir.
  • Fosphenytoin Rifampin may decrease the effect of fosphenytoin.
  • Gadoxetate Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal.
  • Gefitinib Rifampin reduces levels and efficacy of gefitinib
  • Gliclazide Rifampin may decrease the effect of sulfonylurea, gliclazide.
  • Glimepiride Rifampin may decrease the effect of sulfonylurea, glimepiride.
  • Glipizide Rifampin may decrease the effect of sulfonylurea, glipizide.
  • Glisoxepide Rifampin may decrease the effect of sulfonylurea, glisoxepide.
  • Glyburide Rifampin may decrease the effect of sulfonylurea, glibenclamide.
  • Glycodiazine Rifampin may decrease the effect of sulfonylurea, glycodiazine.
  • Haloperidol The rifamycin decreases the effect of haloperidol
  • Hydrocortisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone.
  • Imatinib Rifampin decreases levels of imatinib
  • Imipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed.
  • Indinavir Rifampin decreases the effect of indinavir
  • Itraconazole Rifampin may decrease the effect of itraconazole.
  • Ivacaftor Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely.
  • Josamycin The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.
  • Ketoconazole Rifampin may decrease the effect of ketoconazole.
  • Lamotrigine Rifampin decreases levels of lamotrigine
  • Leflunomide Rifampin increases the effect of leflunomide
  • Linagliptin CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely.
  • Losartan Rifampin decreases the effect of losartan
  • Lovastatin Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed.
  • Mefloquine Rifampin lowers mefloquine levels
  • Mephenytoin Rifampin decreases the effect of the hydantoin
  • Mestranol This product may cause a slight decrease of contraceptive effect
  • Methadone The rifamycin decreases the effect of methadone
  • Methylprednisolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone.
  • Metoprolol Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism.
  • Mexiletine Rifampin decreases the effect of mexiletine
  • Midazolam Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed.
  • Mirabegron Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely.
  • Morphine Rifampin decreases the effect of morphine/codeine
  • Mycophenolate mofetil Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided.
  • Nelfinavir Rifampin decreases the effect of nelfinavir
  • Nifedipine Rifampin decreases the effect of the calcium channel blocker, nifedipine.
  • Norethindrone This product may cause a slight decrease of contraceptive effect
  • Nortriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed.
  • Ospemifene Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect.
  • Oxtriphylline Rifampin may decrease the effect and toxicity of oxtriphylline.
  • Paramethasone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone.
  • Pazopanib Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib.
  • Phenytoin Rifampin may decrease the therapeutic and adverse effects of phenytoin.
  • Pitavastatin Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
  • Pitavastatin Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
  • Pomalidomide Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided.
  • Ponatinib Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
  • Ponatinib Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely.
  • Praziquantel Significant decrease in praziquantel level
  • Prednisolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone.
  • Prednisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.
  • Propafenone Rifampin decreases the effect of propafenone
  • Propranolol Rifampin may decrease the serum concentration of propranolol by increasing its metabolism.
  • Protriptyline The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed.
  • Quinidine Rifampin decreases the effect of quinidine
  • Quinidine barbiturate Rifampin decreases the effect of quinidine
  • Ramelteon Rifampin reduces the levels/effect of ramelteon
  • Regorafenib Strong CYP3A4 inducers may decrease levels of regorafenib.
  • Repaglinide Rifampin decreases the effect of repaglinide
  • Rilpivirine Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy.
  • Ritonavir Rifampin decreases the effect of ritonavir
  • Roflumilast Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism.
  • Rosiglitazone Rifampin reduces levels and efficacy of rosiglitazone
  • Ruxolitinib Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient.
  • Saquinavir Rifampin decreases the effect of saquinavir
  • Saxagliptin Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases.
  • Simvastatin Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed.
  • Sirolimus The rifamycin decreases the effect of sirolimus
  • Sunitinib Possible decrease in sunitinib levels
  • Tacrolimus Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered.
  • Tadalafil Rifampin may reduce Tadalafil plasma concentrations and efficacy.
  • Tamoxifen The rifamycin decreases the effect of anti-estrogen
  • Telaprevir Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated.
  • Telithromycin Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided.
  • Temsirolimus Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.
  • Terbinafine Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure.
  • Theophylline Rifampin decreases the effect of theophylline
  • Tipranavir Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended.
  • Tocainide Rifampin lowers tocainide levels/effects
  • Tofacitinib Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity.
  • Tolazamide Rifampin may decrease the effect of sulfonylurea, tolazamide.
  • Tolbutamide Rifampin may decrease the effect of sulfonylurea, tolbutamide.
  • Tolvaptan Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects.
  • Toremifene The rifamycin decreases the effect of anti-estrogen
  • Tramadol Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance.
  • Trazodone The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed.
  • Tretinoin The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed.
  • Triamcinolone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone.
  • Triazolam Rifampin may decrease the effect of the benzodiazepine, triazolam.
  • Trimethoprim Rifampin decreases the effect of trimethoprim
  • Trimipramine The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed.
  • Ulipristal Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
  • Valproic Acid Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed.
  • Vandetanib Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.
  • Vemurafenib Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely.
  • Verapamil Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed.
  • Voriconazole Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated.
  • Warfarin Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism.
  • Zaleplon Rifampin decreases the effect of zaleplon
  • Zidovudine Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng : Capsule - Oral
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Rifampin 150 mg capsule
    Giá bán buôn : USD >2.27
    Đơn vị tính : capsule
  • Biệt dược thương mại : Rimactane 300 mg capsule
    Giá bán buôn : USD >2.35
    Đơn vị tính : capsule
  • Biệt dược thương mại : Rifampin 300 mg capsule
    Giá bán buôn : USD >2.37
    Đơn vị tính : capsule
  • Biệt dược thương mại : Rifadin 150 mg capsule
    Giá bán buôn : USD >2.57
    Đơn vị tính : capsule
  • Biệt dược thương mại : Rifadin 300 mg capsule
    Giá bán buôn : USD >3.09
    Đơn vị tính : capsule
  • Biệt dược thương mại : Rifampin powder
    Giá bán buôn : USD >3.98
    Đơn vị tính : g
  • Biệt dược thương mại : Rifampin crystals
    Giá bán buôn : USD >6.72
    Đơn vị tính : g
  • Biệt dược thương mại : Rifampin iv 600 mg vial
    Giá bán buôn : USD >136.3
    Đơn vị tính : vial
  • Biệt dược thương mại : Rifadin iv 600 mg vial
    Giá bán buôn : USD >140.9
    Đơn vị tính : vial
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Rifadin
  • Công ty :
    Sản phẩm biệt dược : Rifadine
  • Công ty :
    Sản phẩm biệt dược : Rifaldin
  • Công ty :
    Sản phẩm biệt dược : Rifoldin
  • Công ty :
    Sản phẩm biệt dược : Rimactan
  • Công ty :
    Sản phẩm biệt dược : Rimactane
  • Công ty :
    Sản phẩm biệt dược : Rofact
  • Công ty :
    Sản phẩm biệt dược : Tubocin
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01045
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C06688
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00211
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0904-5282-06
PharmGKB
http://www.pharmgkb.org/drug/PA451250
Wikipedia
http://en.wikipedia.org/wiki/Rifampin
RxList
http://www.rxlist.com/cgi/generic2/rifampin.htm
Drugs.com
http://www.drugs.com/cdi/rifampin.html
... loading
... loading